Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Abstract Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance...

Full description

Bibliographic Details

Published in:	EMBO Molecular Medicine
Main Authors:	Jörg T Regula, Peter Lundh von Leithner, Richard Foxton, Veluchamy A Barathi, Chui Ming Gemmy Cheung, Sai Bo Bo Tun, Yeo Sia Wey, Daiju Iwata, Miroslav Dostalek, Jörg Moelleken, Kay G Stubenrauch, Everson Nogoceke, Gabriella Widmer, Pamela Strassburger, Michael J Koss, Christian Klein, David T Shima, Guido Hartmann
Format:	Article
Language:	English
Published:	Springer Nature 2016-10-01
Subjects:	age‐related macular degeneration angiogenesis angiopoietin‐2 Fc receptor vascular endothelial growth factor
Online Access:	https://doi.org/10.15252/emmm.201505889